

Milena Sokolowska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2255799/publications.pdf>

Version: 2024-02-01

72
papers

6,652
citations

94269

37
h-index

85405

71
g-index

81
all docs

81
docs citations

81
times ranked

10270
citing authors

#	ARTICLE	IF	CITATIONS
1	Environment-dependent alterations of immune mediators in urban and rural South African children with atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 569-581.	2.7	14
2	One Health: EAACI Position Paper on coronaviruses at the human-animal interface, with a specific focus on comparative and zoonotic aspects of SARS-CoV-2. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 55-71.	2.7	19
3	Experimental rhinovirus infection induces an antiviral response in circulating B cells which is dysregulated in patients with asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 130-142.	2.7	10
4	Cellular and molecular mechanisms of allergic asthma. Molecular Aspects of Medicine, 2022, 85, 100995.	2.7	71
5	Nutrient supplementation for prevention of viral respiratory tract infections in healthy subjects: A systematic review and meta-analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1373-1388.	2.7	37
6	Increased circulating CRTH2 ⁺ Tregs are associated with asthma control and exacerbation. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 681-685.	2.7	10
7	Understanding uncontrolled severe allergic asthma by integration of omic and clinical data. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1772-1785.	2.7	17
8	T regulatory cells from atopic asthmatic individuals show a Th2-like phenotype. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1320-1324.	2.7	10
9	Alpine altitude climate treatment for severe and uncontrolled asthma: An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 1991-2024.	2.7	21
10	COVID-19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicals: EAACI recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2313-2336.	2.7	12
11	Effects of non-steroidal anti-inflammatory drugs and other eicosanoid pathway modifiers on antiviral and allergic responses: EAACI task force on eicosanoids consensus report in times of COVID-19. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2337-2354.	2.7	9
12	Leukocyte redistribution as immunological biomarker of corticosteroid resistance in severe asthma. Clinical and Experimental Allergy, 2022, 52, 1183-1194.	1.4	5
13	Role of dietary fiber in promoting immune health: An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 3185-3198.	2.7	48
14	Current perspective on eicosanoids in asthma and allergic diseases: EAACI Task Force consensus report, part I. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 114-130.	2.7	40
15	Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy. Journal of Allergy and Clinical Immunology, 2021, 147, 1865-1877.	1.5	61
16	Risk factors for severe and critically ill COVID-19 patients: A review. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 428-455.	2.7	904
17	SARS-CoV-2 candidate vaccines: composition, mechanisms of action and stages of clinical development. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1922-1924.	2.7	23
18	Perinatal and Early-Life Nutrition, Epigenetics, and Allergy. Nutrients, 2021, 13, 724.	1.7	82

#	ARTICLE	IF	CITATIONS
19	Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1640-1660.	2.7	72
20	EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1629-1639.	2.7	99
21	The Importance of Metabolism for Immune Homeostasis in Allergic Diseases. Frontiers in Immunology, 2021, 12, 692004.	2.2	17
22	Dangerous liaisons: Bacteria, antimicrobial therapies, and allergic diseases. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3276-3291.	2.7	9
23	Management of anaphylaxis due to COVID-19 vaccines in the elderly. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2952-2964.	2.7	16
24	Advances and highlights in biomarkers of allergic diseases. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 3659-3686.	2.7	84
25	Recent advances and developments in COVID-19 in the context of allergic diseases. Clinical and Translational Allergy, 2021, 11, e12065.	1.4	7
26	EAACI position paper on diet diversity in pregnancy, infancy and childhood: Novel concepts and implications for studies in allergy and asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 497-523.	2.7	101
27	Highlights of Novel Vaccination Strategies in Allergen Immunotherapy. Immunology and Allergy Clinics of North America, 2020, 40, 15-24.	0.7	17
28	Mechanisms of Subcutaneous and Sublingual Aeroallergen Immunotherapy. Immunology and Allergy Clinics of North America, 2020, 40, 1-14.	0.7	42
29	Outsmarting SARS-CoV-2 by empowering a decoy ACE2. Signal Transduction and Targeted Therapy, 2020, 5, 260.	7.1	7
30	Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1564-1581.	2.7	828
31	A compendium answering 150 questions on COVID-19 and SARS-CoV-2. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2503-2541.	2.7	95
32	Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2829-2845.	2.7	403
33	T cell requirement and phenotype stability of house dust mite-induced neutrophil airway inflammation in mice. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2970-2973.	2.7	3
34	Immunology of COVID-19: Mechanisms, clinical outcome, diagnostics, and perspectives”A report of the European Academy of Allergy and Clinical Immunology (EAACI). Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2445-2476.	2.7	132
35	The Role of Lung and Gut Microbiota in the Pathology of Asthma. Immunity, 2020, 52, 241-255.	6.6	329
36	Advances and recent developments in asthma in 2020. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 3124-3146.	2.7	94

#	ARTICLE	IF	CITATIONS
37	Allergen-specific immunotherapy: Power of adjuvants and novel predictive biomarkers. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2061-2063.	2.7	21
38	Acute Respiratory Barrier Disruption by Ozone Exposure in Mice. <i>Frontiers in Immunology</i> , 2019, 10, 2169.	2.2	55
39	<sc>EAACI</sc> Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 855-873.	2.7	191
40	EAACI position paper: Influence of dietary fatty acids on asthma, food allergy, and atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1429-1444.	2.7	103
41	Gene expression signatures of circulating human type 1, 2, and 3 innate lymphoid cells. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2321-2325.	1.5	24
42	Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients. <i>Nature Communications</i> , 2019, 10, 5711.	5.8	141
43	The Influence of Dietary Fatty Acids on Immune Responses. <i>Nutrients</i> , 2019, 11, 2990.	1.7	181
44	Bacterial secretion of histamine within the gut influences immune responses within the lung. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 899-909.	2.7	58
45	Role of Der p 1-specific B cells in immune tolerance during 2 years of house dust mite-specific immunotherapy. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1077-1086.e10.	1.5	67
46	Der p 1-specific regulatory T cell response during house dust mite allergen immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 976-985.	2.7	60
47	Key Points for Moving the Endotypes Field Forward. , 2019, , 107-114.		2
48	Tight junction, mucin, and inflammasome-related molecules are differentially expressed in eosinophilic, mixed, and neutrophilic experimental asthma in mice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 294-307.	2.7	109
49	Ozone exposure induces respiratory barrier biphasic injury and inflammation controlled by IL-33. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 942-958.	1.5	93
50	Recent developments and highlights in mechanisms of allergic diseases: Microbiome. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2314-2327.	2.7	90
51	Mechanisms of allergen-specific immunotherapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 306-312.	0.5	105
52	Microbiome and asthma. <i>Asthma Research and Practice</i> , 2018, 4, 1.	1.2	117
53	Regulation of bronchial epithelial barrier integrity by type 2 cytokines and histone deacetylases in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 93-103.	1.5	154
54	Dysregulation of lipidomic profile and antiviral immunity in response to hyaluronan in patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1379-1383.	1.5	42

#	ARTICLE	IF	CITATIONS
55	Troglitazone, a PPAR- β agonist, decreases LTC 4 concentration in mononuclear cells in patients with asthma. <i>Pharmacological Reports</i> , 2017, 69, 1315-1321.	1.5	5
56	Highlights in immune response, microbiome and precision medicine in allergic disease and asthma. <i>Current Opinion in Immunology</i> , 2017, 48, iv-ix.	2.4	15
57	Anionic surfactants and commercial detergents decrease tight junction barrier integrity in human keratinocytes. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 890-893.e9.	1.5	67
58	Interleukins (from IL-1 to IL-38), interferons, transforming growth factor β , and TNF- α : Receptors, functions, and roles in diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 984-1010.	1.5	612
59	The whole - genome expression analysis of peripheral blood mononuclear cells from aspirin sensitive asthmatics versus aspirin tolerant patients and healthy donors after in vitro aspirin challenge. <i>Respiratory Research</i> , 2015, 16, 147.	1.4	4
60	Prostaglandin E2 Inhibits NLRP3 Inflammasome Activation through EP4 Receptor and Intracellular Cyclic AMP in Human Macrophages. <i>Journal of Immunology</i> , 2015, 194, 5472-5487.	0.4	140
61	NOX Modifiers – Just a Step Away from Application in the Therapy of Airway Inflammation?. <i>Antioxidants and Redox Signaling</i> , 2015, 23, 428-445.	2.5	9
62	The Step Further to Understand the Role of Cytosolic Phospholipase A ₂ Alpha and Group X Secretory Phospholipase A ₂ in Allergic Inflammation: Pilot Study. <i>BioMed Research International</i> , 2014, 2014, 1-9.	0.9	15
63	Exacerbating Factors Induce Different Gene Expression Profiles in Peripheral Blood Mononuclear Cells from Asthmatics, Patients with Chronic Obstructive Pulmonary Disease and Healthy Subjects. <i>International Archives of Allergy and Immunology</i> , 2014, 165, 229-243.	0.9	13
64	The fish oil ingredient, docosahexaenoic acid, activates cytosolic phospholipase A ₂ via GPR120 receptor to produce prostaglandin E ₂ and plays an anti-inflammatory role in macrophages. <i>Immunology</i> , 2014, 143, 81-95.	2.0	91
65	Low Molecular Weight Hyaluronan Activates Cytosolic Phospholipase A ₂ and Eicosanoid Production in Monocytes and Macrophages. <i>Journal of Biological Chemistry</i> , 2014, 289, 4470-4488.	1.6	87
66	Changes in microRNA and mRNA Expression with Differentiation of Human Bronchial Epithelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2013, 49, 384-395.	1.4	51
67	Research needs in allergy: an EAACI position paper, in collaboration with EFA. <i>Clinical and Translational Allergy</i> , 2012, 2, 21.	1.4	127
68	Does ADAM17 Cause the Destruction of Anchoring Fibers via Shedding Tumor Necrosis Factor α in Bullous Pemphigoid and Dermatitis Herpetiformis?. <i>Journal of Cutaneous Medicine and Surgery</i> , 2012, 16, 149-150.	0.6	1
69	The 10th anniversary of the Junior Members and Affiliates of the European Academy of Allergy and Clinical Immunology. <i>Pediatric Allergy and Immunology</i> , 2011, 22, 754-757.	1.1	5
70	Cytosolic phospholipase A ₂ group IVA is overexpressed in patients with persistent asthma and regulated by the promoter microsatellites. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 125, 1393-1395.	1.5	28
71	Cytosolic phospholipase A ₂ group IVA influence on GM-CSF expression in human lung cells: a pilot study. <i>Medical Science Monitor</i> , 2010, 16, BR300-6.	0.5	4
72	Variable expression of cysteinyl leukotriene type I receptor splice variants in asthmatic females with different promoter haplotypes. <i>BMC Immunology</i> , 2009, 10, 63.	0.9	9